Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease BEFREE P40 and NUT were not expressed (0/23 and 0/20, respectively) The SMARCA4-DTS immunohistochemical signature was both sensitive and specific, with only a subset of small cell carcinoma of the ovary hypercalcemic type showing overlapping phenotypes. 30451731 2019
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease BEFREE One such perturbation is the dual loss of the SMARCA4 and SMARCA2 ATPase subunits in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)<sup>2-5</sup>, SMARCA4-deficient thoracic sarcomas<sup>6</sup> and dedifferentiated endometrial carcinomas<sup>7</sup>. 30858614 2019
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease BEFREE Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). 29423809 2018
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease BEFREE Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical Models. 28292935 2017
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 GeneticVariation disease BEFREE Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. 29102090 2017
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 GeneticVariation disease BEFREE SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type. 28608987 2017
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease BEFREE The most successful approaches that have been clinically validated so far include the targeting of the BRD4-NUT fusion transcript in NUT-midline carcinoma by BET (Bromodomain Extra-Terminal) inhibitors, and the use of EZH2 (Enhancer of Zest Homolog 2) inhibitors in SMARCB1-deficient malignant rhabdoid tumors and SMARCA4-deficient ovarian small cell carcinomas. 28426098 2017
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 AlteredExpression disease BEFREE Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. 26564006 2016
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 GeneticVariation disease BEFREE We focus on adult granulosa cell tumours (somatic monoallelic mutations in FOXL2), Sertoli-Leydig cell tumours, gynaecological embryonal rhabdomyosarcomas (germline and somatic mutations in DICER1), and small-cell carcinoma of the ovary, hypercalcaemic type (biallelic mutations in SMARCA4). 27504996 2016
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease BEFREE Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. 26356327 2016
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease BEFREE In conclusion, SMARCA4 immunohistochemistry represents a highly valuable emerging tool in identifying small cell carcinoma of the ovary, hypercalcemic type in routine practice. 26123103 2015
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 GeneticVariation disease BEFREE Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). 25307865 2015
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease CTD_human To help define the nosological relationships of these tumors, we compared their transcriptomic profiles with those of SMARCA4-mutated small-cell carcinomas of the ovary, hypercalcemic type (SCCOHTs), SMARCB1-inactivated malignant rhabdoid tumors (MRTs) and lung carcinomas (of which 10% display SMARCA4 mutations). 26343384 2015
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 GeneticVariation disease BEFREE Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. 24658004 2014
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 GeneticVariation disease BEFREE Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. 24658002 2014
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease CTD_human Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. 24658004 2014
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease CTD_human Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. 24658002 2014
CUI: C0262584
Disease: Carcinoma, Small Cell
Carcinoma, Small Cell
0.400 Biomarker disease CTD_human Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. 24658001 2014